What Happens When You Stop

GLP-1 medications work well while you're on them. The trial data on what happens after you stop is some of the clearest, and most important, evidence in this entire category.

Most conversations about GLP-1 medications like semaglutide and tirzepatide focus on what happens while you're taking them. Fewer focus on what happens afterward, whether by choice, cost, or access. The trial evidence on that question is unusually clear, and it changes how the decision to start should probably be framed in the first place.

What the withdrawal trial actually found

The STEP 1 trial randomized 1,961 adults without diabetes to 68 weeks of semaglutide or placebo, alongside a lifestyle intervention. At week 68, everyone stopped treatment, including the lifestyle support. A follow-up extension then tracked 327 of those participants for another year off the drug.

Through week 68, the semaglutide group lost an average of 17.3 percent of body weight, compared to 2.0 percent on placebo. After stopping, by week 120, the semaglutide group had regained 11.6 percentage points of that loss on average. Net weight loss from baseline settled at 5.6 percent, down from 17.3 percent at the peak. The trial's own authors describe this as participants regaining two-thirds of their prior weight loss, and their stated conclusion is direct: the findings "confirm the chronicity of obesity and suggest ongoing treatment is required" to maintain results.

Cardiometabolic improvements measured during treatment, things like blood pressure and blood sugar markers, mostly reverted toward baseline by week 120 as well.

One detail matters for interpreting this fairly: the lifestyle support was withdrawn at the exact same time as the medication. That's not typically how people stop in real life, and it likely makes this trial's regain numbers closer to a worst case scenario than an average one. It's also worth noting the extension analysis was exploratory, drawing on a convenience subset of participants rather than a fully randomized sample, so the precision of the exact percentages shouldn't be overstated even as the overall direction is consistent with other data below.

Tirzepatide tells a similar story, with more detail on the range of outcomes

A separate trial, SURMOUNT-4, took a more targeted approach. Participants who had already lost at least 10 percent of their body weight over 36 weeks on tirzepatide were then randomized to either continue the medication or switch to placebo for another year.

In the placebo group, 82 percent regained more than a quarter of the weight they had lost. But the full distribution is more useful than that single number: of 308 people in the placebo arm, 54 regained less than a quarter of their lost weight, 77 regained a quarter to half, 103 regained half to three quarters, and 74, about one in four, regained three quarters or more. Roughly one in six people held on to most of what they'd lost. Roughly one in four gave back nearly all of it. Averages hide that range, and the range is the more honest way to think about your own odds.

What actually happens outside of a trial

Real world data tells a related but distinct story about how many people stay on these medications at all, independent of whether the drug works. An analysis from Prime Therapeutics, a pharmacy benefit manager, found that 71 percent of people prescribed a GLP-1 for weight loss discontinued it within one year, and 85 percent within two years. For weekly semaglutide specifically, only about one in four people were still on it at the two year mark.

It's worth being direct about who produced that data and why it matters. Prime Therapeutics manages drug benefits for health plans and has a financial interest in the cost these medications represent, and it also markets its own adherence programs. That doesn't make the underlying claims data inaccurate, claims data reflects what actually happened, but the choice to lead with a discontinuation statistic isn't a neutral one, and it's worth knowing that the entity reporting high discontinuation rates has an interest in framing GLP-1 use as a cost problem. It's a useful mirror to the previous article's finding, where the reassuring take on muscle loss came from sources with pharmaceutical industry ties. Here, the concerning take on discontinuation comes from a source with a payer-side financial interest. Both are worth knowing before weighing the numbers.

Why people actually stop is only partly answered

The trial and real world data both establish that stopping is common and that regain after stopping is substantial. What's harder to pin down is exactly why people stop in the first place. Side effects are part of it, gastrointestinal issues like nausea and diarrhea are common enough on these medications that some people discontinue specifically because of them, though in the original trials only around 7 percent of people stopped for that reason, far lower than the roughly 70 percent real world one year discontinuation rate. That gap suggests cost, insurance coverage, and access are doing a large share of the work, not tolerability alone.

That context matters given a recent shift in the market. An oral form of semaglutide received FDA approval in December 2025 as the first oral GLP-1 for chronic weight management, and it launched with a starter dose priced at 149 dollars a month for cash paying patients. Pricing and access remain moving targets in this category, and they're relevant to any decision about starting a medication that the evidence above suggests is meant to be taken long term to keep its benefits.

What this means if you're deciding whether to start

None of this is an argument against these medications. It's an argument for going in with an accurate picture of what they are: for most people, based on the best available evidence, they function more like an ongoing treatment for a chronic condition than a course you complete. The weight loss achieved while on treatment is real and often substantial, but the data consistently shows that stopping, for whatever reason, tends to bring much of it back within a year. That's worth factoring into a conversation with a clinician before starting, not discovering afterward.

Want a quick starting point?

If you're weighing whether a GLP-1 medication fits your situation, including what a realistic long-term plan looks like, our Find Your Care quiz can help point you toward the right next conversation with a clinician.

Frequently asked questions

Does this mean weight regain after stopping is guaranteed?
No. The SURMOUNT-4 data shows a real range of outcomes, and some people held on to most of their weight loss even after stopping. But the majority in these trials regained a substantial share, and the honest expectation should account for that range rather than assuming you'll land at the favorable end.

If I have to stay on this long term, is that a bad thing?
Not inherently. Many chronic conditions are managed with ongoing medication, and the trial authors themselves frame obesity this way. The main implication is practical: the cost, access, and long-term commitment involved should be part of the decision from the start, not a surprise later.

Why do so many more people stop in the real world than in the trials?
The trials didn't track this question directly, but the gap between roughly 7 percent trial discontinuation for side effects and 71 percent real world discontinuation within a year strongly suggests cost, insurance coverage, and access play a larger role outside of a research setting than tolerability alone does.

Does the newer oral version change any of this?
It changes the cost and access picture somewhat, since it launched at a specific price point for cash paying patients in December 2025, but the underlying evidence on regain after stopping comes from injectable semaglutide and tirzepatide trials and would need its own long-term data to confirm whether the same pattern holds.

The bottom line

The clearest, best-documented finding in this entire category may be the simplest one: stopping a GLP-1 medication tends to bring back a substantial share of the weight it took off, whether that's measured in a controlled trial or in real-world claims data. Real-world data also shows most people stop within one to two years, for reasons that appear to go well beyond side effects alone. None of this means these medications aren't worth using. It means the decision to start is better made with a realistic view of what stopping tends to look like, since for most people, based on the evidence so far, staying on track requires staying on treatment.

This article is for general education and is not medical advice.

Sources

‹ Why You Stopped Sleeping, and What the Trials Actually Say Works

What You Actually Lose on a GLP-1 ›